Benign metastasising leiomyoma is a rare disease occuring predominantly in women of childbearing age and is hormonally influenced. The response of the disease to the luteinising hormone releasing hormone analogue goserelin is reported.
Benign metastasising leiomyoma is a rare disease which is part of a spectrum that also includes lymphangioleiomyomatosis. The two disorders are histologically distinct but both are hormonally influenced and remission has been reported following menopause or surgical castration. 1 16acobson, Rainey, Turton The patient was initially given the progesterone analogue, medroxyprogesterone acetate, and oxygen for 16 hours daily. A month later tamoxifen was added. Progesterone was stopped in December 1989 due to side effects of ear, jaw, and throat pains. The disease showed no response to this treatment regimen which was discontinued in March 1990. The LHRH analogue goserelin was then given in a dose of 3 6 mg subcutaneously monthly. Before treatment arterial blood gas tensions were Po2 6-7 kPa, Pco2 5-4 kPa, pH 7-41 breathing air. Since that time there has been a slow but consistent improvement. Symptomatically the patient is managing well at home after 42 months of treatment. The chest radiograph has improved (fig 2) and in October 1993 arterial blood gas tensions breathing air were Po, 8-2 kPa, Pco2 4.7 kPa, pH 7*43.
Discussion
Benign metastasising leiomyoma is a rare disease usually restricted to women ofchildbearing age with previous uterine fibroids. Histological examination shows smooth muscle tumours at a distant site, usually the lungs, which appear benign in that there are few mitotic figures, no nuclear pleomorphism, and no invasion. There are similarities of clinical expression, hormonal dependence, and histological appearance with lymphangioleiomyomatosis. However, lymphangioleiomyomatosis is more rapidly progressive, it may be complicated by pneumothoraces, and radiographically it shows an interstitial pattern of infiltration rather than a macronodular appearance. Histologically, the tumour nodules in benign metastasising leiomyoma are larger, and spare lymphatic vessels, blood vessels, airways, and air spaces and are not associated with emphysematous changes.
Cases with intermediate features have been described.'
In our case treatment with the LHRH analogue goserelin was followed by regression, though failure of similar treatment has been reported.6 The patient's menopausal status was not documented endocrinologically before treatment and she had had a hysterectomy. However, there were no systemic menopausal symptoms before treatment, while flushes and sweats were very troublesome soon after commencing goserelin. It seems much more likely that improvement was due to treatment than a spontaneous menopause.
The contradiction inherent in the term "benign metastasising leiomyoma" is unsatisfactory. Perhaps it reflects our poor understanding of the pathophysiology of the disease and its rarity. Multicentre treatment trials are not practicable, but a central register of cases would help further research and advance understanding. 
